Covidien has extended agreement with Allergan to jointly promote Allergan’s LAP-BAND System, the adjustable gastric band for bariatric surgery, in the US.
The LAP-BAND Adjustable Gastric Banding System is the FDA approved gastric band for use in weight reduction.
The LAP-BAND System is approved for use with severely obese adults or with adults who have a BMI of at least 35, along with at least one severe obesity-related health condition, such as type 2 diabetes, hypertension or asthma.
The LAP-BAND AP System, launched in 2007, is the latest addition to the LAP-BAND System family. The LAP-BAND AP System incorporates the proprietary 360º Omniform technology and offers reliability based on advanced technology and proven performance, said the company.
Jerry Liebrand, president of surgical devices business for US at Covidien, said: “At Covidien, we seek to be the partner of choice, collaborating with bariatric professionals, leading researchers and industry partners such as Allergan to provide innovative options for resolving diabetes and significantly reducing obesity.”
Jim Caggiano, vice president of health sales and marketing for Allergan Medical at Allergan, said: “It provides us with the opportunity to expand our field sales force efforts and further progress our work to educate and train surgeons regarding the benefits of the LAP-BAND System.”